Background As mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes …
H Walach, RJ Klement, W Aukema - Vaccines, 2021 - mdpi.com
Background: COVID-19 vaccines have had expedited reviews without sufficient safety data. We wanted to compare risks and benefits. Method: We calculated the number needed to …
We report that in a cohort of 45,965 adults, who were receiving either the ChAdOx1 or the BNT162b2 SARS-CoV-2 vaccines, in those who had no prior infection with SARS-CoV-2 …
N Koerber, A Priller, S Yazici, T Bauer… - Nature …, 2022 - nature.com
Anti-viral immunity continuously declines over time after SARS-CoV-2 infection. Here, we characterize the dynamics of anti-viral immunity during long-term follow-up and after …
The current surgein infections with the SARS-CoV-2 Delta variant has made it clear to health care workers and the public alike that fully vaccinated people remain at risk for SARS-CoV-2 …
Six months of COVID vaccines: what 1.7 billion doses have taught scientists. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …
On July 8, 2021, Pfizer and BioNTech announced they would be seeking US and European authorization for administration of a third booster dose of their COVID-19 vaccine. 1 The …
Booster vaccination with messenger RNA (mRNA) vaccines has been offered to adults in England starting on 14 September 2021. We used a test-negative case–control design to …
There is a public health need to understand how different frequencies of COVID-19 booster vaccines may mitigate the risk of severe COVID-19, while accounting for waning of …